Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential targeted-activated CIK cells plus PD-1 antibody for advanced liver cancer
ChiCTR2200059813Phase 2Not yet recruiting
- Sponsor
- Beijing GoBroad Boren Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of PD-1 Monoclonal Antibody, sponsored by Beijing GoBroad Boren Hospital. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibody
Beyond the preview
Go deeper on ChiCTR2200059813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059813.